Kidney Res Clin Pract.  2022 Nov;41(6):682-698. 10.23876/j.krcp.21.285.

Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors

• Chan ATP
• Tang SCW

• KMID: 2540197
• DOI: http://doi.org/10.23876/j.krcp.21.285

Abstract

Progress in the treatment of diabetic kidney disease (DKD) has been modest since the early trials on renin-angiotensin-aldosterone system inhibitors (RAASis). Although sodium-glucose co-transporter 2 inhibitors (SGLT2is) have revolutionized the management of DKD by lowering proteinuria and protecting organs, other novel treatment approaches with good evidence and efficacy that can be used in conjunction with a RAASi or SGLT2i in managing DKD have emerged in the past few years. This review discusses the evidence for glucagon-like peptide-1 receptor agonist, selective mineralocorticoid receptor antagonist, and selective endothelin A receptor antagonist, emerging treatment options for DKD beyond SGLT2 inhibition.

Keyword

Diabetic kidney disease; Diabetic nephropathies; Glucagon-like peptide-1 receptor agonist; Non-steroidal mineralocorticoid receptor antagonist; Selective endothelin receptor antagonist; Sodium-glucose transporter 2 inhibitors